Abstract
A prospective non-randomized study was conducted to determine the effectiveness, toxicity and tolerance of Methotrexate (MTX) as initial therapy in patients with advanced head and neck squamous cell carcinoma (H & N Cancer). Eighty patients were given two courses of 100 mg/m2 MTX by i. v. route as abolus at fifteen days interval without Leucovorin rescue. Patients were evaluated for response two weeks after the second course. Response rate was as high as 26.6% CR (Complete Regression) and 42.6% PR (Partial regression) in primary lesion, while it was 8% CR and 42.6% PR in secondaries (regional lymph nodes). This schedule seems to be effective, cheap, well tolerable and can be used on out-patient basis.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
